Efficacy of nomograms based on Japanese patients which predict clinical outcomes of prostate cancer
Kuroiwa, K.
Nihon Rinsho. Japanese Journal of Clinical Medicine 74(Suppl 3): 183-187
2016
ISSN/ISBN: 0047-1852 PMID: 27344726 Document Number: 688323
Document emailed within 1 workday
Related Documents
Murray, N.P.; Aedo, S.óc.; Reyes, E.; Fuentealba, C.; Jacob, O. 2019: Primary circulating prostate cells, age and prostatic volumen predict the presence of prostate cancer in men with indication of a second prostate biopsy Archivos Espanoles de Urologia 72(1): 16-24Ngo, L.S.M.; Yeo, A.; Wong, A.S.C.; Tay, M.Hiang. 2007: Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore Annals of the Academy of Medicine Singapore 36(10): 811-814
Imaizumi, H.; Ishibashi, K.; Okada, N.; Tajima, Y.; Amano, K.; Hatano, S.; Kuwabara, K.; Sobajima, J.; Ishiguro, T.; Ohsawa, T.; Kumamoto, K.; Kumagai, Y.; Haga, N.; Ishida, H. 2012: Clinical outcomes in refractory colorectal cancer patients with wild-type K-ras treated with bevacizumab and oxaliplatin-based chemotherapy as a first-line treatment Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(12): 2185-2188
Azuma, K.; Kawakami, K.; Yuasa, T.; Sugisaki, T.; Hashimoto, K.; Aoyama, T.; Suzuki, K.; Yonese, J.; Hama, T. 2018: Safety Profile of the Combination of Prophylactic Pegfilgrastim and Cabazitaxel for Japanese Patients with Castration Resistant Prostate Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(12): 1737-1742
Galbraith, M.E.; Ramirez, J.M.; Pedro, L.W. 2001: Quality of life, health outcomes, and identity for patients with prostate cancer in five different treatment groups Oncology Nursing Forum 28(3): 551-560
Mei, Q.; Ye, L.; Chen, C.; Lin, H. 2020: Clinical trial evaluating efficacy and safety of pemetrexed based chemotherapy regimen versus ramucirumab plus erlotinib in Chinese patients with lung cancer: a preliminary investigation Pakistan Journal of Pharmaceutical Sciences 33(5(Special): 2379-2384
Zhang, Y.; Lei, B.-H.; Zou, Q.; Zhu, Q.-Y.; Lu, Z.-J.; Wang, Y. 2017: Clinical efficacy of integrated traditional Chinese and Western medicine for castration-resistant prostate cancer Zhonghua Nan Ke Xue 23(10): 922-927
Wang, W.; Peng, R.-x.; Shi, G.-w.; Chen, S.-y.; Ding, Q.; He, J.-y. 2015: Treatment of castration-resistant prostate cancer: Evidence-based clinical practice Zhonghua Nan Ke Xue 21(12): 1121-1124
Ichikawa, W. 2011: Recent advancement in biomarkers to predict the clinical outcome for colorectal cancer patients Nihon Rinsho. Japanese Journal of Clinical Medicine 69 Suppl. 3: 220-225
Stenman, U.H.; Leinonen, J.; Alfthan, H.; Rannikko, S.; Tuhkanen, K.; Alfthan, O. 1991: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer Cancer Research 51(1): 222-226
Serdar, M.A.; Oguz, O.; Olgun, A.; Seçkin, B.; Ilgan, S.; Hasimi, A.; Salih, M.; Peker, F.; Kutluay, T. 2002: Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together Annals of Clinical and Laboratory Science 32(1): 22-30
Yamaguchi, K.; Watanabe, M.; Nakamura, M.; Konomi, H.; Tanaka, M. 2006: Japanese guidelines for treatment of pancreatic cancer based on evidence-based medicine Nihon Rinsho. Japanese Journal of Clinical Medicine 64 Suppl. 1: 180-185
Isomura, S.; Suzuki, S.; Sato, Y. 1985: Clinical efficacy of the Japanese acellular pertussis vaccine after intrafamiliar exposure to pertussis patients Developments in Biological Standardization 61: 531-537
Okihara, K. 2016: Current status and future perspective in Japanese prostate cancer screening Nihon Rinsho. Japanese Journal of Clinical Medicine 74 Suppl. 3: 275-279
Koga, T.; Okada, A.; Kawashiri, S.; Kita, J.; Suzuki, T.; Nakashima, Y.; Tamai, M.; Satoh, K.; Origuchi, T.; Iwamoto, N.; Yamasaki, S.; Nakamura, H.; Migita, K.; Ida, H.; Ueki, Y.; Eguchi, K.; Kawakami, A. 2011: Soluble urokinase plasminogen activator receptor as a useful biomarker to predict the response to adalimumab in patients with rheumatoid arthritis in a Japanese population Clinical and Experimental Rheumatology 29(5): 811-815
Watanabe, M.; Fukutome, K.; Murata, M.; Uemura, H.; Kubota, Y.; Kawamura, J.; Yatani, R. 1999: Significance of vitamin D receptor gene polymorphism for prostate cancer risk in Japanese Anticancer Research 19(5c): 4511-4514
Suzuki, K.; Ohtake, N.; Nakata, S.; Takei, T.; Matsui, H.; Ono, Y.; Nakazato, H.; Hasumi, M.; Koike, H.; Ito, K.; Fukabori, Y.; Kurokawa, K.; Yamanaka, H. 2002: Association of HPC2/ELAC2 polymorphism with prostate cancer risk in a Japanese population Anticancer Research 22(6b): 3507-3511
Ragde, H.; Grado, G.L.; Nadir, B.S. 2001: Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone Archivos Espanoles de Urologia 54(7): 739-747
Liu, B.-q.; Wu, Y.-d.; Wei, J.-x.; Zhang, T.; Liu, R.-l.; Ma, T.-x. 2007: Expression of prostate cancer antigen-1 in prostate cancer and its clinical significance Zhonghua Nan Ke Xue 13(11): 997-1001
Gao, J.; Cong, H.-l.; Mao, Y.-m.; Liu, Y.; Zhang, N.; Chen, Q.; Liu, T.; Cui, R.-z. 2013: Effects of genetic variations of cholesteryl ester transfer protein on atorvastatin treatment efficacy and clinical outcomes in patients with coronary artery disease Zhonghua Yi Xue Za Zhi 93(28): 2195-2199